Conclusions
NMIBC
In this single-center retrospective cohort study of 312 patients treated over a single decade, patients treated with adjuvant gemcitabine and docetaxel for high-risk NMIBC after TURBT had improved high-grade RFS and less treatment discontinuation compared with those treated with BCG. While awaiting results from an ongoing randomized clinical trial and in the setting of the current BCG shortage, the findings of this study support the use of gemcitabine and docetaxel for the treatment of high-risk NMIBC, suggesting that this regimen can be considered for recommendation in updated practice guidelines. Further prospective evaluation is needed.